Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
Mario Gaudino, MD, PhD, spoke to Cardiovascular Business about minimally invasive procedures, the growing interest in clinical trials and other key trends in the world of cardiac surgery.
ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.
The Philips Azurion interventional imaging system was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.
Researchers tracked data from nearly 400 women with complex CAD who underwent treatment with Shockwave Medical's intravascular lithotripsy technology prior to PCI.
Even seeing a cardiologist once per year can help these patients elevate their long-term survival. Many stay home, however, missing out on potentially life-saving guidance and/or treatment.
